论文部分内容阅读
目的探讨上海地区肺癌患者表皮生长因子受体(EGFR)突变情况,以及其与临床特征之间的相关性。方法收集207例上海地区肺癌患者石蜡组织样本,提取DNA后采用实时荧光定量聚合酶链反应(ARMS-PCR)技术检测EGFR突变。结果上海地区肺癌患者的EGFR突变率为47.34%,并与性别、病理分类有相关性(P<0.01),与年龄无相关性(P>0.05)。EGFR突变类型与性别、年龄均无相关性(P>0.05)。肺腺癌患者EGFR突变状况与其腺癌的病理分类无相关性(P>0.05)。结论上海地区EGFR突变与肺癌患者的临床特征相关,女性突变率高于男性,肺腺癌患者突变率高于其他类型肺癌患者。
Objective To investigate the mutation of epidermal growth factor receptor (EGFR) in patients with lung cancer in Shanghai area and its correlation with clinical features. Methods Totally 207 paraffin-embedded specimens of lung cancer patients were collected from Shanghai area. DNA was extracted and the EGFR mutation was detected by real-time fluorescent quantitative polymerase chain reaction (ARMS-PCR). Results The EGFR mutation rate of lung cancer patients in Shanghai was 47.34%. There was a correlation between sex and pathological classification (P <0.01) and no correlation with age (P> 0.05). There was no correlation between EGFR mutation types and gender and age (P> 0.05). There was no correlation between EGFR mutation status and pathological classification of adenocarcinoma in patients with lung adenocarcinoma (P> 0.05). Conclusion The EGFR mutation in Shanghai is related to the clinical characteristics of patients with lung cancer. The mutation rate of female patients is higher than that of male patients. The mutation rate of lung adenocarcinoma patients is higher than that of other types of lung cancer patients.